Will Teva Pharmaceutical Industries Limited (NYSE:TEVA) be Surging after Earnings Report?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) moved down -0.4% and closed its last trading session at $32.25. This Medical Sector stock currently has the Market Capitalization of 32.38 Billion. The Average Volume for the stock is measured as 10.79 Million. The Stock has a 52-Week High of $59.35 and 52-Week Low of $31.9 following the dates, it touched its 52-Week High on Mar 11, 2016 and 52-Week Low on Feb 8, 2017. Currently, the Return on Assets value for the trailing twelve months is 2.4% with the Return on Equity and Return on Investment of 5.7% and 5.7% respectively. This firm currently has YTD (year to date) performance of -11.03 Percent which is not good. The Short Ratio for the stock is 1.85.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Price to Earnings (P/E) ratio is 18.63. EPS or Earning per Share stands at $1.73. The TTM operating margin is 15.9 percent.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) reports its Earnings on Mon 13 Feb (In 4 Days). The estimated EPS for the current quarter is said to be $1.32. Following Earnings result, share price were DOWN 13 times out of last 19 Qtrs. The stock has reduced about -20.3% since it reported its last earnings. The Closing price of Teva Pharmaceutical Industries Limited (NYSE:TEVA) at Last Earnings was $40.65 as compared to the previous closing price of $32.38. The Predicted Move on the 7th day after Teva Pharmaceutical Industries Limited (NYSE:TEVA) will release its earnings at about 2%.

By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, Teva Pharmaceutical Industries Limited (NYSE:TEVA) beats earnings by 75%, The Stock Missed Earnings  1 times and has met earnings  2  times.

Earnings History:

We will discuss the past Quarters Earnings below:

Teva Pharmaceutical Industries Limited (NYSE:TEVA) reported its previous quarter on 11/15/2016 where it reported the Actual Earnings of $1.31. The Closing price before the company posted its earnings was $40.65. The Stock declined on the very next day of earnings and maintained its stock price at $37.25 by showing a % change of -8.36 percent from its previous closing price. The Next Day Volume after Earnings was reported as 27.15 Million. On the 7th day After Earnings Report, the stock hit its share price as $38.44 by showing -5.44% decrease from the Stock price Before Earnings were reported.

On 08/04/2016, the stock reported the EPS of $1.25 where Analysts were projecting the EPS to be $1.2 showing a difference of $0.05. Thus Surprise Factor was there with 4.2 percent. Before Earnings Announcement on 08/04/2016, the firm had its stock price of $52.74. And immediately on the next day after earnings announcement, the stock inclined 3.51% and closed its trading session at $54.59. On 7th Day after earnings release, Teva Pharmaceutical Industries Limited (NYSE:TEVA) dropped to -1.8% from $52.74 to $51.79.

On 05/09/2016, Analysts were suspecting EPS of $1.17/share where Teva Pharmaceutical Industries Limited (NYSE:TEVA) reported its Actual EPS of $1.2. Thus showing a Surprise of 2.6 percent. The Closing Price of the stock before earnings was $49.17 while on the Next day the stock closed its trading session at $51.65 with a percentage change of 5.04% from the price of 49.17 before Earnings. The Stock Closing Price on the 7th day of earnings was $49.2.

Company Profile:

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company’s Generic Medicines segment offers generic medicines, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The company’s Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women’s health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Nuvigil for the treatment of excessive sleepiness associated with narcolepsy and certain other disorders; Fentora/Effentora for the treatment of breakthrough pain in opioid-tolerant adult patients with cancer; and Zecuity, a prescription transdermal system for the acute treatment of migraine with or without aura in adults. This segment’s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, and Duoresp Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda, Granix, Trisenox, Synribo, Lonquex, Myocet, Eporatio, Tevagrastim/Ratiograstim, and Trisenox products in the oncology market. This segment also offers a portfolio of products in the women’s health category, which includes ParaGard, Plan B One-Step, OTC/Rx, Zoely, Seasonique, and Ovaleap, as well as other products. Teva Pharmaceutical Industries Limited has collaboration arrangements with Takeda Pharmaceutical Company Limited, Procter & Gamble Company, Intel, and Regeneron Pharmaceuticals, Inc. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.